ARCA biopharma Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Tom Keuer
Chief executive officer
US$400.8k
Total compensation
| CEO salary percentage | 84.8% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.005% |
| Management average tenure | no data |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Companies Like ARCA biopharma (NASDAQ:ABIO) Can Afford To Invest In Growth
Apr 04
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Sep 24ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play
May 03Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Mar 18Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
Nov 27Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Jul 15Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
Mar 30Enrollment underway in ARCA bio's mid-stage AB201 study in COVID-19
Dec 15We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth
Dec 15
ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment
Nov 24ARCA biopharma reports Q3 results
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | US$401k | US$340k | -US$5m |
| Sep 30 2023 | n/a | n/a | -US$5m |
| Jun 30 2023 | n/a | n/a | -US$6m |
| Mar 31 2023 | n/a | n/a | -US$8m |
| Dec 31 2022 | US$449k | US$340k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$17m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$421k | US$339k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$19m |
| Jun 30 2021 | n/a | n/a | -US$16m |
| Mar 31 2021 | n/a | n/a | -US$13m |
| Dec 31 2020 | US$631k | US$285k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$6m |
| Jun 30 2020 | n/a | n/a | -US$5m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$304k | US$283k | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$327k | US$303k | -US$8m |
| Sep 30 2018 | n/a | n/a | -US$11m |
| Jun 30 2018 | n/a | n/a | -US$13m |
| Mar 31 2018 | n/a | n/a | -US$17m |
| Dec 31 2017 | US$457k | US$302k | -US$18m |
Compensation vs Market: Tom's total compensation ($USD400.80K) is below average for companies of similar size in the US market ($USD670.12K).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
CEO
Tom Keuer (64 yo)
9.3yrs
Tenure
US$400,802
Compensation
Mr. Thomas A. Keuer, also known as Tom, serves as President & Principal Executive Officer of ARCA Biopharma, Inc. since April 3, 2024 and has been the Chief Operating Officer since December 1, 2014. Mr. Ke...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 16.9yrs | US$162.50k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$150.00k | 0% $ 0 | |
| Independent Chairman of the Board | 10.6yrs | US$195.00k | 0.34% $ 179.0k | |
| Director | 1.8yrs | US$130.00k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$40.00k | 0% $ 0 |
7.2yrs
Average Tenure
57yo
Average Age
Experienced Board: ABIO's board of directors are considered experienced (7.2 years average tenure).